Enfortumab Vedotin Continues to Show Benefit in Urothelial Cancer

Jonathan E. Rosenberg, MD, chief of Genitourinary Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses what has been previously shown with enfortumab vedotin (Padcev) for patients with locally advanced metastatic urothelial cancer.

In a dose-escalation and dose-expansion cohort (cohort A) of the multi-cohort, open-label, multicenter EV-103 study (NCT03288545), treatment with enfortumab vedotin elicited an overall response rate (ORR) of 73%. The median survival for patients was 26.6 months.

Data presented at the European Society for Medical Oncology Congress 2022 support further investigations of enfortumab vedotin plus pembrolizumab (Keytruda) in the first-line for patients with locally advanced metastatic urothelial cancer.

Transcription:

0:08 | There was a dose escalation and dose expansion cohort A of EV-103, which enrolled about 45 patients total. It showed that the ORR was 73% in that patient population of patients with cisplatin ineligible metastatic urothelial cancer. The [median] overall survival in that cohort was an impressive 26.2 months, which is roughly at least double of what you might expect with gemcitabine and carboplatin based on historical data.

0:41 | I suspect it is better than the current treatment paradigm of chemotherapy followed by maintenance of nivolumab, although there have not been any randomized trials. That first cohort has led to the development of subsequent trials, which are testing enfortumab vedotin and pembrolizumab further.